SEC Form SC 13G filed by RenovoRx Inc.

4/14/22 2:24:24 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RNXT alert in real time by email

SC 13G 1 BOTW-13G-RenovoRX-Plain.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. __) RenovoRx Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75989R107 (CUSIP Number) March 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |X| Rule 13d-1(b) |_| Rule 13d-1(c) |_|Rule 13d-1(d) CUSIP NO. 75989R107 1 Name Of Reporting Persons Bank of the West, Trustee of the Mars16 Nevada Non-Grantor Trust Dtd 01/19/2016 2 Check The Appropriate Box If A Member Of A Group (See Instructions) (a) |_| (b) |_| 3 SEC Use Only 4 Citizenship Or Place Of Organization California 5 Sole Voting Power Number of 975,000 Shares 6 Shared Voting Power 0 Beneficially Owned By 7 Sole Dispositive Power 0 Each Reporting 8 Shared Dispositive Power Person With 0 9 Aggregate Amount Beneficially Owned By Each Reporting Person 975,000 [1] 10 Check If The Aggregate Amount In Row (9) Excludes Certain Shares X (See Item 4(c)) 11 Percent Of Class Represented By Amount In Row 9 10.79% [2] 12 Type Of Reporting Person (See Instructions) BK [1]975,000 shares of common stock are held of record by Bank of the West, Trustee of the Mars16 Nevada Non-Grantor Trust Under Agreement Dated January 19, 2016. As trustee, Bank of the West maintains the sole voting power, while Kamran Najmabadi, who serves as the Investment Advisor of said trust, maintains sole dispositive power over the RenovoRx, Inc stock held in the Mars16 Nevada Non-Grantor Trust. [2]Based on 9,029,305 shares of the Issuer's common stock outstanding as of March 25, 2022, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on March 30, 2022. Item 1 (a). Name of Issuer: RenovoRx Inc. Item 1 (b). Address of Issuer's Principal Executive Offices: RenovoRX Inc. 4546 El Camino Real Suite B1 Los Altos, CA 92606 650.284.4433 Item 2 (a). Name of Person Filing: Bank of the West Item 2 (b). Address of Principal Business Office: 180 Montgomery St. San Francisco, CA 94104 Item 2 (c). Citizenship: United States Item 2 (d). Title of Class of Securities: Common Item 2 (e). CUSIP Number: 75989R107 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) |_| Broker or dealer registered under Section 15 of the Act. (b) |X| Bank as defined in Section 3(a)(6) of the Act. (c) |_| Insurance company as defined in Section 3(a)(19) of the Act. (d) |_| Investment company registered under Section 8 of the Investment Company Act. (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E); (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) |_| A parent holding company, in accordance with Rule 13d-1(b)(ii)(G); (h) |_| A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned: 975,000 (b) Percent of Class: 10.79% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 975,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class: Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: Not Applicable Item 8. Identification and Classification of Members of the Group: Not Applicable Item 9. Notice of Dissolution of Group. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: April 14, 2022 Bank of the West, Trustee of the Mars16 Nevada Non-Grantor Trust Dtd 01/19/2016 By: /s/ Wade Balliet EVP and Head of Global Investments & Fiduciary Solutions Signature

Get the next $RNXT alert in real time by email

Date

Price Target

Rating

Analyst

11/1/2021

$16.00

Buy

Roth Capital

10/6/2021

$15.00

Buy

Maxim Group

SEC Form SC 13G filed by RenovoRx Inc.

4/14/22 2:24:24 PM ET

$RNXT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RNXT alert in real time by email

Date

Price Target

Rating

Analyst

11/1/2021

$16.00

Buy

Roth Capital

10/6/2021

$15.00

Buy

Maxim Group

SEC Form SC 13G filed by RenovoRx Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RNXT

SEC Form SC 13G filed by RenovoRx Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RNXT

$RNXT
Insider Trading

Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

SEC Form 4 filed by Bagai Shaun

SEC Form 4 filed by Voll Mark

$RNXT
Press Releases

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

$RNXT
SEC Filings

Amendment: SEC Form 10-K/A filed by RenovoRx Inc.

SEC Form 10-Q filed by RenovoRx Inc.

RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$RNXT
Analyst Ratings

Roth Capital initiated coverage on RenovoRx with a new price target

Maxim Group initiated coverage on RenovoRx with a new price target

$RNXT
Insider Purchases

Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

$RNXT
Financials

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

$RNXT
Leadership Updates

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

$RNXT
Large Ownership Changes

SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)